BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the underwriters of its previously announced underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share have exercised in full their option to purchase an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions. After giving effect to the closing on February 26, 2018, and the additional closing completed today, Aimmune estimates gross proceeds from the offering to be approximately $202.4 million.
BofA Merrill Lynch, Cantor Fitzgerald & Co. and Piper Jaffray & Co. are acting as joint bookrunning managers for the offering. Credit Suisse and RBC Capital Markets are also acting as bookrunning managers. Roth Capital Partners and Wedbush PacGrow are acting as co-managers for the offering.
A registration statement relating to the securities being sold in this offering was filed with the Securities and Exchange Commission on December 28, 2017, and was automatically declared effective upon filing. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: BofA Merrill Lynch, NC1-004-03, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, email: email@example.com; or from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022; email: firstname.lastname@example.org; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for potentially life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age and is currently being evaluated in Phase 3 clinical trials.